口服和单克隆疾病修正治疗多发性硬化症患者的感染缓解策略。
Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies.
机构信息
Department of Neurology, NYU-Multiple Sclerosis Care Center, NYU School of Medicine, New York, NY, USA.
, New York, NY, USA.
出版信息
Curr Neurol Neurosci Rep. 2021 May 19;21(7):36. doi: 10.1007/s11910-021-01117-y.
Abstract
PURPOSE OF REVIEW
The newer, higher-efficacy disease-modifying therapies (DMTs) for multiple sclerosis (MS)-orals and monoclonals-have more profound immunomodulatory and immunosuppressive properties than the older, injectable therapies and require risk mitigation strategies to reduce the risk of serious infections. This review will provide a systematic framework for infectious risk mitigation strategies relevant to these therapies.
RECENT FINDINGS
We classify risk mitigation strategies according to the following framework: (1) screening and patient selection, (2) vaccinations, (3) antibiotic prophylaxis, (4) laboratory and MRI monitoring, (5) adjusting dose and frequency of DMT, and (6) behavioral modifications to limit the risk of infection. We systematically apply this framework to the infections for which risk mitigations are available: hepatitis B, herpetic infections, progressive multifocal leukoencephalopathy, and tuberculosis. We also discuss up-to-date recommendations regarding COVID-19 vaccinations for patients on DMTs. We offer a practical, comprehensive, DMT-specific framework of derisking strategies designed to minimize the risk of infections associated with the newer MS therapies.
摘要
目的综述
新型高效多发性硬化症（MS）治疗药物（DMT）-口服药和单克隆抗体比传统的注射型 DMT 具有更强的免疫调节和免疫抑制作用，因此需要采取风险缓解策略来降低严重感染的风险。本篇综述将提供一个与这些治疗药物相关的感染风险缓解策略的系统框架。
最新发现
我们根据以下框架对风险缓解策略进行分类：（1）筛查和患者选择，（2）疫苗接种，（3）抗生素预防，（4）实验室和 MRI 监测，（5）调整 DMT 的剂量和频率，以及（6）行为改变以限制感染的风险。我们系统地将这一框架应用于有可用风险缓解措施的感染：乙型肝炎、疱疹感染、进行性多灶性白质脑病和结核病。我们还讨论了针对正在接受 DMT 治疗的患者的 COVID-19 疫苗接种的最新建议。我们提供了一个实用、全面、针对 DMT 的风险降低策略框架，旨在最大程度地降低与新型 MS 治疗相关的感染风险。
相似文献
1
Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies.口服和单克隆疾病修正治疗多发性硬化症患者的感染缓解策略。
Curr Neurol Neurosci Rep. 2021 May 19;21(7):36. doi: 10.1007/s11910-021-01117-y.
2
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.多发性硬化症和视神经脊髓炎谱系障碍疾病修正治疗的感染风险：第八届欧洲多发性硬化症治疗与研究委员会重点研讨会综述。2021 年 4 月。
Mult Scler. 2022 Aug;28(9):1424-1456. doi: 10.1177/13524585211069068. Epub 2022 Feb 23.
3
Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.多发性硬化症：现有和新兴的疾病修正治疗方法和治疗策略。
Mayo Clin Proc. 2014 Feb;89(2):225-40. doi: 10.1016/j.mayocp.2013.11.002.
4
Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England.大规模疫苗接种对英国使用免疫调节疾病修正疗法的多发性硬化症患者中 SARS-CoV-2 感染的影响。
Mult Scler Relat Disord. 2022 Jan;57:103458. doi: 10.1016/j.msard.2021.103458. Epub 2021 Dec 5.
5
Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.多发性硬化症的疾病修正治疗与 COVID-19 大流行：感染风险和未来疫苗接种的影响。
CNS Drugs. 2020 Sep;34(9):879-896. doi: 10.1007/s40263-020-00756-y.
6
Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.在接受疾病修正治疗的多发性硬化症患者中，SARS-CoV-2 感染的临床病程和结局-波兰经验。
Neurol Neurochir Pol. 2021;55(2):212-222. doi: 10.5603/PJNNS.a2021.0031. Epub 2021 Apr 15.
7
Analysis of seroconversion following COVID-19 vaccination among multiple sclerosis patients treated with disease-modifying therapies in Poland.波兰接受疾病修正疗法治疗的多发性硬化症患者接种 COVID-19 疫苗后的血清转化率分析。
Neurol Neurochir Pol. 2024;58(1):112-119. doi: 10.5603/pjnns.96425. Epub 2024 Jan 22.
8
COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review.COVID-19 与中枢神经系统脱髓鞘疾病患者的疾病修正治疗：系统评价。
Mult Scler Relat Disord. 2021 May;50:102800. doi: 10.1016/j.msard.2021.102800. Epub 2021 Jan 29.
9
Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.多发性硬化症患者感染 COVID-19 的风险：一项病例对照研究。
Neurol Neuroimmunol Neuroinflamm. 2022 Jan 19;9(2). doi: 10.1212/NXI.0000000000001141. Print 2022 Mar.
10
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.多发性硬化症患者的 COVID-19：与疾病修正治疗的关联
CNS Drugs. 2021 Mar;35(3):317-330. doi: 10.1007/s40263-021-00804-1. Epub 2021 Mar 20.
引用本文的文献
1
Vaccine-Induced Humoral and Cellular Response to SARS-CoV-2 in Multiple Sclerosis Patients on Ocrelizumab.接受奥瑞珠单抗治疗的多发性硬化症患者对SARS-CoV-2的疫苗诱导体液和细胞反应。
Vaccines (Basel). 2025 Apr 30;13(5):488. doi: 10.3390/vaccines13050488.
2
Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: A practical review.鞘氨醇 1-磷酸受体调节剂在多发性硬化症治疗中的应用：实践综述。
Ann Clin Transl Neurol. 2024 Apr;11(4):842-855. doi: 10.1002/acn3.52017. Epub 2024 Feb 16.
3
Assisted Reproductive Technology and Disease Management in Infertile Women with Multiple Sclerosis.患有多发性硬化症的不孕女性的辅助生殖技术与疾病管理
CNS Drugs. 2023 Oct;37(10):849-866. doi: 10.1007/s40263-023-01036-1. Epub 2023 Sep 7.
4
Infections among individuals with multiple sclerosis, Alzheimer's disease and Parkinson's disease.多发性硬化症、阿尔茨海默病和帕金森病患者的感染情况。
Brain Commun. 2023 Mar 16;5(2):fcad065. doi: 10.1093/braincomms/fcad065. eCollection 2023.
5
Summary of Safety and Efficacy of COVID Vaccination in Patients with Multiple Sclerosis.多发性硬化症患者 COVID 疫苗接种的安全性和有效性总结。
Eur Neurol. 2023;86(4):263-276. doi: 10.1159/000529982. Epub 2023 Mar 4.
6
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis.治疗初发缓解型多发性硬化症的高效疗法。
CNS Drugs. 2022 Dec;36(12):1285-1299. doi: 10.1007/s40263-022-00965-7. Epub 2022 Nov 9.
7
Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapies.COVID-19 疫苗接种可引起多发性硬化症患者强烈的 T 细胞激活，此类患者正在接受 B 细胞耗竭治疗。
Front Immunol. 2022 Aug 5;13:926318. doi: 10.3389/fimmu.2022.926318. eCollection 2022.
8
SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19.SARS-CoV-2 感染多发性硬化症患者：与 COVID-19 治疗、辅助疗法和疫苗的相互作用。
J Neurol. 2022 Sep;269(9):4581-4603. doi: 10.1007/s00415-022-11237-1. Epub 2022 Jul 5.
9
Risk of serious infections in multiple sclerosis patients by disease course and disability status: Results from a Swedish register-based study.基于疾病进程和残疾状态的多发性硬化症患者严重感染风险：一项瑞典基于登记册的研究结果。
Brain Behav Immun Health. 2022 May 11;22:100470. doi: 10.1016/j.bbih.2022.100470. eCollection 2022 Jul.
10
The Expanding Role of the Infectious Disease Expert in the Context of the MS Centre.传染病专家在多发性硬化症中心背景下不断扩大的作用。
J Pers Med. 2022 Apr 7;12(4):591. doi: 10.3390/jpm12040591.
本文引用的文献
1
Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy.奥瑞珠单抗单药治疗进展性多发性硬化症患者的进行性多灶性脑白质病。
JAMA Neurol. 2021 Jun 1;78(6):736-740. doi: 10.1001/jamaneurol.2021.0627.
2
Prevalence of Latent Tuberculosis in the Multiple Sclerosis Clinic and Effect of Multiple Sclerosis Treatment on Tuberculosis Testing.多发性硬化症诊所中潜伏性结核病的患病率及多发性硬化症治疗对结核病检测的影响
Int J MS Care. 2021 Jan-Feb;23(1):26-30. doi: 10.7224/1537-2073.2019-015. Epub 2020 Apr 14.
3
Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment.评估和减轻接受疾病修饰治疗的多发性硬化症患者的感染风险。
Expert Rev Clin Immunol. 2021 Mar;17(3):285-300. doi: 10.1080/1744666X.2021.1886924. Epub 2021 Mar 8.
4
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.疾病修正疗法与多发性硬化症中 2019 年冠状病毒病严重程度。
Ann Neurol. 2021 Apr;89(4):780-789. doi: 10.1002/ana.26028. Epub 2021 Feb 9.
5
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.Ad26.COV2.S 新冠疫苗 1/2a 期临床试验的中期结果。
N Engl J Med. 2021 May 13;384(19):1824-1835. doi: 10.1056/NEJMoa2034201. Epub 2021 Jan 13.
6
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
7
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
8
Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis.在意大利一个大型多发性硬化症患者群体中，不同那他珠单抗间隔给药方案的临床效果。
J Neurol Neurosurg Psychiatry. 2020 Dec;91(12):1297-1303. doi: 10.1136/jnnp-2020-323472. Epub 2020 Oct 14.
9
The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement.多发性硬化症患者接受疾病修正治疗后的感染风险：德尔菲共识声明。
Mult Scler. 2021 Mar;27(3):331-346. doi: 10.1177/1352458520952311. Epub 2020 Sep 17.
10
Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis.评估伊朗多发性硬化症患者 COVID-19 感染、住院和死亡的发生率。
Mult Scler Relat Disord. 2020 Nov;46:102472. doi: 10.1016/j.msard.2020.102472. Epub 2020 Aug 29.
Zotero 插件